• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Novo Integrated Sciences Stock Is Up

    5/31/24 1:02:53 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials
    Get the next $NVOS alert in real time by email

    Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares are trading higher Friday after the company announced its board is conducting a review to determine whether it is appropriate to increase the company's stock repurchase program.

    The Details:

    Novo announced the board of directors is conducting a strategic review to determine whether it is appropriate to increase the maximum amount that can be repurchased pursuant to the stock repurchase program based on the amount, if any, of excess funds that may be generated from the recently disclosed program to monetize a Standby Letter of Credit intended to complete the Ophir Collection acquisition. 

    Pending receipt of funds from the unsecured 15-year $70 million promissory note with RC Consulting Consortium Group, LLC in favor of SCP Tourbillion Monaco for a lump sum debt funding of $57 million less fees and expenses, the amount and timing of any shares repurchased under the Stock Repurchase Program will be determined at the discretion of management.

    Related News: UiPath Stock Plummets After Q1 Results: Here’s Why

    Novo shares are racing higher on heavy trading volume following the announcement. According to data from Benzinga Pro, more than 213 million shares have already been traded in the session, compared to the stock’s 100-day average of 1.027 million shares.

    Is NVOS A Good Stock To Buy?

    An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Novo Integrated Sciences‘ page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

    These are known as capital allocation programs. Novo Integrated Sciences does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

    For example, if you're looking to earn an annualized return of 15.37%, you'll need to buy a share of ARMOUR Residential REIT by June 17, 2024. Once done, you can expect to receive a nominal payout of $0.24 on June 27, 2024.

    Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Novo Integrated Sciences will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

    NVOS Price Action: According to Benzinga Pro, Novo Integrated Sciences shares are up 133% at $1.05 at the time of publication Friday.

    Image: Pete Linforth from Pixabay

    Get the next $NVOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer David Christopher Mehlin

    4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

    9/12/24 6:05:09 AM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by David Christopher Mehlin

    4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

    6/2/23 4:05:37 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Novo Integrated Sciences Inc.

    4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

    8/10/22 1:01:17 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    $NVOS
    SEC Filings

    View All

    SEC Form SEC STAFF ACTION filed by Novo Integrated Sciences Inc.

    SEC STAFF ACTION - Novo Integrated Sciences, Inc. (0001138978) (Filer)

    5/20/25 9:00:03 AM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    Novo Integrated Sciences Inc. filed SEC Form 8-K: Leadership Update

    8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)

    5/6/25 4:30:35 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    Novo Integrated Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)

    5/2/25 4:13:03 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    $NVOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results

    Novo Integrated Sciences, Inc. (OTC:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2024. Robert Mattacchione, the Company's CEO and Board Chairman, stated, "The Company remains committed to the commercialization of its proprietary product offerings and the expansion and delivery of its essential services and solutions to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and

    12/18/24 4:05:00 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

    Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the third fiscal quarter ended May 31, 2024. Robert Mattacchione, Novo's CEO and Board Chairman, stated, "The Company's fiscal year 2024 third quarter emphasized maximizing operational efficiencies for all business units. The Company continues to work with certain prospective financial partners to close previously announced non-traditional financing opportunities to raise foundation

    7/19/24 5:00:00 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program

    Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit ("SBLC"). The initial disbursement represents the first payment as per the arrangement creating a release of lien resulting in the subsequent final advance to the Company. With this initial disbursement the Company expects final distribution to follow on or before August 2. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SBLC monetizatio

    7/18/24 4:05:00 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    $NVOS
    Leadership Updates

    Live Leadership Updates

    View All

    Novo Integrated Sciences Appoints New President

    Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces today Mr. Robert Oliva has been appointed as the Company's new President. Mr. Oliva succeeds Mr. Christopher David, who remains as the Company's Chief Operating Officer and as a member of the Company's Board of Directors. Mr. Oliva has over 35 years of ownership and proven business development with expertise in manufacturing related operations. Mr. Oliva is expected to advance the Company's product-related operational efficiency while managing aggressive, yet sustainable growth and improving margins. Robert Mattacchione, the Company's CEO and Board Chairman, stated, "The addition of Mr. Oliva comes at a tim

    2/16/24 2:00:00 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    Novo Integrated Sciences Appoints Dr. Indrajit (Indra) Sinha Ph.D. as Chief Science Officer

    Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces that Dr. Indrajit "Indra" Sinha, Ph.D. has been appointed as Novo's Chief Science Officer, effective June 24, 2021. Dr. Sinha brings over 25 years of experience in various areas of cross-disciplinary translational research, drug development, biotechnology, technology transfer, and biopharmaceutical compliance. His work has been extensively published in highly reputed peer reviewed journals. Through his passion for utilizing under-appreciated technologies and applying them in innovative ways to achieve previously unattainable outcomes, he has created various intellectual property and patents. Robert Mattacchio

    7/7/21 8:00:00 AM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    $NVOS
    Financials

    Live finance-specific insights

    View All

    Novo Integrated Sciences Completes Acquisition of Clinical Consultants International LLC

    Dr. Joseph M. Chalil, MD, MBA, FACHE Appointed Chief Medical Officer and the New President of Novomerica Health Group Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced the Company has completed the acquisition of Clinical Consultants International LLC ("CCI"), a global consulting firm, based in Boca Raton, Florida, specializing in providing value-added services for the pharmaceutical, biotech, healthcare management, hospital management, medical marketing and strategic planning, health policy, and medic

    4/7/22 8:00:00 AM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    Novo Integrated Sciences Acquires Majority Stake in Terragenx and Intellectual Property for FDA and Health Canada Approved Water-Soluble Iodine Micro-Nutrient

    Iodine, an essential nutrient, when in aerosolized aqueous form can be safely ingested to kill bacteria and deactivate various viruses Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, announced today it has acquired 91% of Terragenx and the intellectual property portfolio for the unique formulation and manufacturing capability to produce a water-soluble iodine micro-nutrient that is FDA and Health Canada approved for over-the-counter and e-commerce distribution (the "Iodine IP and Patents"). Iodine is a naturally oc

    11/30/21 8:00:00 AM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    Novo Integrated Sciences and Novo Healthnet Limited Complete Acquisition of Acenzia

    Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today Novo Healthnet Limited, a wholly owned subsidiary of the Company ("NHL"), completed the acquisition of Acenzia Inc., a Windsor Canada based company that provides nutraceutical health solutions through advanced bio-science research and development, proprietary manufacturing, and personalized diagnostics. The all-share transaction, which closed on June 24, 2021, is valued at $14,884,039, or $3.91 per share, and is subject to purchase price adjustment within 90 days of the closing date pending completion of an audit and working capital requirement provisions. Robert Mattacchione, Novo's Chairman and CEO, st

    6/29/21 8:00:00 AM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    $NVOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Novo Integrated Sciences Inc. (Amendment)

    SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)

    2/6/24 12:00:24 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Novo Integrated Sciences Inc. (Amendment)

    SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)

    2/10/23 3:45:24 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G filed by Novo Integrated Sciences Inc.

    SC 13G - Novo Integrated Sciences, Inc. (0001138978) (Subject)

    2/8/22 4:28:22 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials